한국메디홀스

비상장계속사업자

hankookmediwholes

정성천

Investment Review Report

Auto-filled from disclosures & public data + AI-drafted analysis. Edit, then export to PDF/DOCX.

Editor

1.Deal Terms

2.Valuation / Exit Assumptions

Exit Scenarios100M KRW

3.Fund Eligibility

Fund mandate eligibility — no data, enter manually

Enter fund mandate requirements and applicability (Y/N) to include a table in the report.

4.Capital Changes

Not in DART — enter capital-raise history manually

Enter capital changes such as founding capital and paid-in increases.

5.Stock Options

Enter manually

Enter stock option grant history.

6.Investment Highlights

AI draft — editable

Click 'Generate AI draft' to populate data-grounded investment highlights.

7.Investment Risks

AI draft — editable

Risks are populated after 'Generate AI draft'.

8.Market Analysis

AI draft — editable

9.Business Analysis

AI draft — editable

10.Conclusion (Investment Opinion)

AI draft — editable

11.P&L Projection

Analyst estimates, manual entry (100M KRW). Generates a trend chart & table.

Enter projected revenue / op. profit / net income (100M KRW) by year to add a trend chart and table.
Preview— the document below is saved as PDF/DOCX

Investment Review Report

한국메디홀스

Business Reg. No. 1208669985 · CEO 정성천

I.Investment Overview

Target한국메디홀스 (1208669985)
Investment
Post-deal stake
ValuationPre — / Post —

II.Investment Highlights

No investment highlights written yet.

III.Investment Risks

No risks written yet.

IV.Company Profile

회사명한국메디홀스
영문명hankookmediwholes
대표자정성천
사업자등록번호1208669985
법인등록번호1101113049859
설립일2004.07.15

V.Financial Summary

Per DART disclosure · in 억/만원 (KRW)

Financial trend (100M KRW)

매출액100M KRW4482021471.82022505.92023554.32024754.92025
영업이익100M KRW47.3202124.3202234.3202339.1202448.42025
순이익100M KRW39.1202129202239.1202338202441.12025
Item20252024202320222021
자산총계558.1억원477.2억원437.1억원293.4억원286.9억원
부채총계264.3억원214.5억원202.5억원90.1억원112.6억원
자본총계293.7억원262.6억원234.7억원203.3억원174.3억원
매출액754.9억원554.3억원505.9억원471.8억원448억원
영업이익48.4억원39.1억원34.3억원24.3억원47.3억원
순이익41.1억원38억원39.1억원29억원39.1억원

VI.Financial Ratios

FY2025 basis

6.42%

영업이익률

5.44%

순이익률

7.36%

ROA

13.99%

ROE

89.99%

부채비율

52.64%

자기자본비율

VII.Valuation & Exit Plan

Exit valuation
Holding period5y
Enter exit assumptions (investment, stake, exit valuation, period) to see MOIC·IRR.

This report compiles disclosure & public data and AI-drafts some sections as a research aid. It is not investment advice; the user bears final responsibility for facts and investment decisions.

한국메디홀스 투심보고서 | Alpha Lenz